The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults ...

The decline was partially offset by higher revenues from generic products globally and strong growth from branded drugs, Austedo, Ajovy and Uzedy, along with the sale of certain product rights.

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...